1058131-55-7

Basic information

• Product Name: oxane-4-sulfonaMide
• Synonyms: oxane-4-sulfonaMide;tetrahydro-2H-pyran-4-sulfonamide
• CAS NO: 1058131-55-7
• Molecular Formula: C₅H₁₁NO₃S
• Molecular Weight: 165.21074
• EINECS: -0
• Mol File: 1058131-55-7.mol

Chemical Properties

• Boiling Point: 328.2±52.0 °C(Predicted)
• Appearance: /
• Density: 1.33±0.1 g/cm3(Predicted)
• PKA: 10.27±0.20(Predicted)
• CAS DataBase Reference: oxane-4-sulfonaMide(CAS DataBase Reference)
• NIST Chemistry Reference: oxane-4-sulfonaMide(1058131-55-7)
• EPA Substance Registry System: oxane-4-sulfonaMide(1058131-55-7)

Safety Data

• Hazardous Substances Data: 1058131-55-7(Hazardous Substances Data)

Usage

Uses

Oxane-4-sulfonamide is used as a PPARα receptor antagonist.

Upstream product

• 1768-64-5 4-chlorotetrahydro-2H-pyran 
• 203246-70-2 thioacetic acid S-(tetrahydro-pyran-4-yl)ester 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.